{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/prostate-cancer/","result":{"data":{"firstChapter":{"id":"324faedd-14d8-5d99-8059-d9428da432ea","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field dfc71ad8-97f6-44cb-83fe-9fcaa6f6ca4f --><h1>Prostate cancer: Summary</h1><!-- end field dfc71ad8-97f6-44cb-83fe-9fcaa6f6ca4f -->","htmlStringContent":"<!-- begin item a1bb49fe-b261-4b26-a2ca-bd60e667c21b --><!-- begin field 9fb9ab49-4ab5-41c8-a3f1-2fe00911066a --><ul><li>Prostate cancer is a malignant tumour of the prostate. Almost all cancers of the prostate (95%) are adenocarcinomas.</li><li>Prostate cancer is multifocal — the different foci may be caused by different genetic mutations, which can differ greatly in growth rate and ability to metastasize.</li><li>Most prostate cancers are indolent and grow slowly — a minority are aggressive and invade local structures or metastasize to remote tissues. <ul><li>Localized prostate cancer usually develops in the outer zone of the prostate, where it seldom causes symptoms.</li><li>Locally advanced prostate cancer extends beyond the capsule of the prostate and is often asymptomatic when diagnosed.</li><li>Metastatic prostate cancer most frequently affects the bones, where it causes pain and fragility fractures. </li></ul></li><li>About 26% of all new cases of cancer in men are prostate cancer — it is the most common type of cancer in men.</li><li>Prostate cancer is the second most common cause of cancer death in males in the UK (after lung cancer), accounting for 13% of all cancer deaths.</li><li>Risk factors for developing prostate cancer include:<ul><li>Increasing age.</li><li>Black ethnicity.</li><li>Family history of prostate cancer.</li><li>Obesity or being overweight.</li></ul></li><li>Prostate cancer should be suspected in men who have any of the following symptoms that are unexplained:<ul><li>Lower back or bone pain.</li><li>Lethargy.</li><li>Erectile dysfunction.</li><li>Haematuria.</li><li>Anorexia/weight loss.</li><li>Lower urinary tract symptoms (LUTS), such as frequency, urgency, hesitancy, terminal dribbling and/or overactive bladder.</li></ul></li><li>Diagnosis of prostate cancer should include:<ul><li>A digital rectal examination (DRE).</li><li>A prostate-specific antigen (PSA) test.</li></ul></li><li>Before PSA testing, the man should carefully consider the benefits and limitations of PSA tests. PSA testing may be offered to:<ul><li>Men older than 50 years of age who ask for a PSA test.</li><li>Men with unexplained symptoms which might be caused by locally advanced or metastatic prostate cancer.</li><li>Men with obstructive LUTS which might be caused by benign prostatic enlargement (which is common) or by locally advanced prostate cancer (which is rare).</li></ul></li><li>Urgent referral to a urological cancer specialist should be arranged if prostate cancer is suspected either because the prostate is hard and nodular on DRE, or because the PSA level is 3.0 nanogram/mL or higher.</li><li>Referral (and PSA testing) may not be appropriate if the man has comorbidities that compromise his clinical state or significantly shorten his life expectancy.</li><li>In secondary care, a man with suspected prostate cancer may be offered a prostate biopsy to confirm or exclude the diagnosis, and imaging to assess the TNM stage of the prostate cancer.</li><li>Treatment for prostate cancer will be initiated and managed in secondary care, and may include:<ul><li>Watchful waiting.</li><li>Active surveillance.</li><li>Radical treatments (such as prostatectomy, or radiotherapy).</li><li>Adjunctive and palliative treatments (such as hormonal treatment, or chemotherapy).</li></ul></li><li>Primary care will be involved in shared care with follow up and monitoring.</li></ul><!-- end field 9fb9ab49-4ab5-41c8-a3f1-2fe00911066a --><!-- end item a1bb49fe-b261-4b26-a2ca-bd60e667c21b -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","aliases":[],"chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","slug":"management","fullItemName":"Management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","aliases":[],"topicSummary":"Prostate cancer is a malignant tumour of the prostate. Almost all cancers of the prostate (95%) are adenocarcinomas.","lastRevised":"Last revised in October 2017","nextPlannedReviewBy":"2022-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2022-09","nextPlannedReviewByDisplay":"September 2022","specialities":[{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"},{"id":"34b90622-9d68-500d-98a2-3c80efbae845","name":"Men's health","slug":"mens-health"}],"chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","slug":"management","fullItemName":"Management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c"}},"staticQueryHashes":["3666801979"]}